학술논문

533PD - BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
Document Type
Abstract
Source
In Annals of Oncology October 2019 30 Supplement 5:v203-v203
Subject
Language
ISSN
0923-7534